Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock

1. BMO Capital downgraded NVO from Outperform to Market Perform. 2. Price target reduced from $105 to $64, indicating bearish outlook. 3. Eli Lilly's drugs are gaining market share from NVO's offerings. 4. Recent trials show Eli Lilly’s tirzepatide outperforming NVO's semaglutide. 5. Upcoming competition may further pressure NVO stock performance.